Four notes:
1. Bioventus posted second quarter net sales of $109.8 million, an 89.3 percent year-over-year increase.
2. The company posted a net loss of $10.8 million, an 80.3 percent increase.
3. Revenue from its pain treatments and joint preservation business was $56.7 million, a 96.4 percent increase. Preservation and restorative therapies revenue increased 80.9 percent with $32.6 million. Bone graft substitutes revenue was $20.6 million, an 84.3 percent increase.
4. Bioventus expects to see net sales of $405 million to $415 million this year.
